Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIP NASDAQ:OCUL NASDAQ:PRTA NASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$91.68-0.4%$88.46$52.50▼$99.50$1.99B0.58372,524 shs239,930 shsOCULOcular Therapeutix$11.52+5.0%$12.28$5.78▼$13.85$2.00B1.452.00 million shs3.73 million shsPRTAProthena$10.17+3.1%$8.34$4.32▼$18.88$547.45M-0.111.03 million shs1.03 million shsVERAVera Therapeutics$30.80-0.5%$23.64$18.53▼$51.61$1.97B1.231.38 million shs925,742 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals+2.70%+0.14%-3.45%+41.48%+59.19%OCULOcular Therapeutix-3.86%-12.45%-19.34%+10.58%+11.48%PRTAProthena-0.60%+1.02%+15.32%+51.23%-41.52%VERAVera Therapeutics+2.65%+7.06%+27.90%+34.52%-24.24%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$91.68-0.4%$88.46$52.50▼$99.50$1.99B0.58372,524 shs239,930 shsOCULOcular Therapeutix$11.52+5.0%$12.28$5.78▼$13.85$2.00B1.452.00 million shs3.73 million shsPRTAProthena$10.17+3.1%$8.34$4.32▼$18.88$547.45M-0.111.03 million shs1.03 million shsVERAVera Therapeutics$30.80-0.5%$23.64$18.53▼$51.61$1.97B1.231.38 million shs925,742 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals+2.70%+0.14%-3.45%+41.48%+59.19%OCULOcular Therapeutix-3.86%-12.45%-19.34%+10.58%+11.48%PRTAProthena-0.60%+1.02%+15.32%+51.23%-41.52%VERAVera Therapeutics+2.65%+7.06%+27.90%+34.52%-24.24%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 3.00Buy$97.296.11% UpsideOCULOcular Therapeutix 2.75Moderate Buy$22.1392.06% UpsidePRTAProthena 2.20Hold$20.50101.57% UpsideVERAVera Therapeutics 2.60Moderate Buy$63.00104.55% UpsideCurrent Analyst Ratings BreakdownLatest PRTA, OCUL, ANIP, and VERA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/7/2025PRTAProthenaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $20.0010/3/2025OCULOcular TherapeutixPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$21.00 ➝ $31.0010/3/2025OCULOcular TherapeutixRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$17.00 ➝ $24.0010/2/2025OCULOcular TherapeutixZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold10/2/2025OCULOcular TherapeutixChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$21.0010/1/2025OCULOcular TherapeutixCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform10/1/2025OCULOcular TherapeutixJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$20.00 ➝ $29.0010/1/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $20.009/27/2025ANIPANI PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C-)9/27/2025OCULOcular TherapeutixWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PRTAProthenaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$614.38M3.24$7.77 per share11.80$19.11 per share4.80OCULOcular Therapeutix$56.66M35.37N/AN/A$2.01 per share5.73PRTAProthena$135.16M4.05N/AN/A$9.05 per share1.12VERAVera TherapeuticsN/AN/AN/AN/A$9.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals-$18.52M-$0.77N/A21.78N/A-1.37%25.03%8.00%11/14/2025 (Estimated)OCULOcular Therapeutix-$193.51M-$1.28N/AN/AN/A-382.51%-71.92%-49.36%11/13/2025 (Estimated)PRTAProthena-$122.31M-$5.64N/AN/AN/A-2,929.30%-62.17%-54.43%11/11/2025 (Estimated)VERAVera Therapeutics-$152.15M-$3.58N/AN/AN/AN/A-46.70%-39.46%11/6/2025 (Estimated)Latest PRTA, OCUL, ANIP, and VERA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025ANIPANI Pharmaceuticals$1.42$1.80+$0.38$0.36$187.18 million$211.37 million8/5/2025Q2 2025OCULOcular Therapeutix-$0.35-$0.39-$0.04-$0.39$13.12 million$13.46 million8/5/2025Q2 2025VERAVera Therapeutics-$0.82-$1.20-$0.38-$1.20N/AN/A8/4/2025Q2 2025PRTAProthena-$1.11-$1.86-$0.75-$2.34$5.36 million$4.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.392.541.96OCULOcular Therapeutix0.2310.1010.02PRTAProthenaN/A5.685.68VERAVera Therapeutics0.1617.0317.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%OCULOcular Therapeutix59.21%PRTAProthena97.08%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals12.70%OCULOcular Therapeutix2.30%PRTAProthena9.20%VERAVera Therapeutics16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.70 million18.94 millionOptionableOCULOcular Therapeutix230174.00 million169.99 millionOptionablePRTAProthena13053.83 million48.88 millionOptionableVERAVera Therapeutics4063.82 million53.42 millionOptionablePRTA, OCUL, ANIP, and VERA HeadlinesRecent News About These CompaniesJ. Safra Sarasin Holding AG Takes Position in Vera Therapeutics, Inc. $VERAOctober 5 at 3:47 AM | marketbeat.comVera Therapeutics, Inc. $VERA Shares Purchased by Platinum Investment Management Ltd.October 2, 2025 | marketbeat.com13,567 Shares in Vera Therapeutics, Inc. $VERA Acquired by GC Wealth Management RIA LLCOctober 2, 2025 | marketbeat.com10,406 Shares in Vera Therapeutics, Inc. $VERA Purchased by Perigon Wealth Management LLCOctober 1, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsSeptember 28, 2025 | americanbankingnews.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of "Moderate Buy" from BrokeragesSeptember 28, 2025 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Shares Up 5.3% - Time to Buy?September 25, 2025 | marketbeat.comKDIGO guidelines positive for Vera Therapeutics, says Cantor FitzgeraldSeptember 19, 2025 | msn.comVoya Investment Management LLC Has $15.07 Million Stock Position in Vera Therapeutics, Inc. $VERASeptember 17, 2025 | marketbeat.comDynamic Technology Lab Private Ltd Makes New $326,000 Investment in Vera Therapeutics, Inc. $VERASeptember 15, 2025 | marketbeat.comSiren L.L.C. Has $17.95 Million Stake in Vera Therapeutics, Inc. $VERASeptember 13, 2025 | marketbeat.comWoodline Partners LP Has $24.04 Million Stock Holdings in Vera Therapeutics, Inc. $VERASeptember 12, 2025 | marketbeat.comVera Therapeutics (VERA) Stock Surges 27% Over Last MonthSeptember 10, 2025 | finance.yahoo.comSamlyn Capital LLC Sells 683,797 Shares of Vera Therapeutics, Inc. $VERASeptember 8, 2025 | marketbeat.comParkman Healthcare Partners LLC Acquires New Stake in Vera Therapeutics, Inc. $VERASeptember 8, 2025 | marketbeat.comCinctive Capital Management LP Cuts Stock Holdings in Vera Therapeutics, Inc. $VERASeptember 8, 2025 | marketbeat.comVera Therapeutics, Inc. $VERA Stock Position Lifted by Trexquant Investment LPSeptember 8, 2025 | marketbeat.comNorthern Trust Corp Sells 36,748 Shares of Vera Therapeutics, Inc. $VERASeptember 8, 2025 | marketbeat.comVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comVera Therapeutics, Inc. (VERA) Presents at Cantor Global Healthcare Conference 2025 TranscriptSeptember 5, 2025 | seekingalpha.comEvercore ISI Sticks to Their Buy Rating for Vera Therapeutics (VERA)August 27, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRTA, OCUL, ANIP, and VERA Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$91.68 -0.38 (-0.41%) Closing price 04:00 PM EasternExtended Trading$91.67 -0.01 (-0.01%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.Ocular Therapeutix NASDAQ:OCUL$11.52 +0.55 (+5.01%) Closing price 04:00 PM EasternExtended Trading$11.44 -0.08 (-0.74%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Prothena NASDAQ:PRTA$10.17 +0.31 (+3.14%) Closing price 04:00 PM EasternExtended Trading$9.88 -0.29 (-2.85%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.Vera Therapeutics NASDAQ:VERA$30.80 -0.14 (-0.45%) Closing price 04:00 PM EasternExtended Trading$30.80 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Dividend Aristocrats to Buy Before Year’s End Joby's Stock Rallies as Public Flights Validate Global Game Plan SharkNinja Is Flashing a Buy Signal the Market Is Ignoring Why Semtech Stock Is Rallying After Its NVIDIA Setback Marvell Insiders Buy Shares—Should Investors Follow Suit? TrumpRx Brings Pfizer Into the Green—Is It a Buy? Behind D-Wave's Massive Week (And Why Rivals Also Popped) Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
